Popular injectable weight-loss medications are effective in helping individuals lose weight and improve health markers. However, as usage increases, doctors are uncovering more potential drawbacks of these GLP-1 targeting drugs.
A recent, non-peer-reviewed Canadian study suggests that GLP-1 drugs may increase the risk of hair loss, particularly in women.
Dr. Mohit Sodhi and his team at the University of British Columbia analyzed data from over 1,900 semaglutide users and 1,300 bupropion-naltrexone (Contrave) users. Semaglutide is found in Ozempic (for diabetes) and Wegovy (for obesity). Sodhi’s research focused on Wegovy users to eliminate any potential impact that diabetes might have on hair loss.
The study compared hair loss diagnoses in patient records. Results showed that semaglutide users had a 50% higher risk of hair loss compared to Contrave users. This risk was twice as high for women.
The exact cause of the link between semaglutide and hair loss is unclear. However, Dr. Sodhi suggests that the physiological stress from rapid and significant weight loss caused by semaglutide may contribute. Semaglutide leads to faster and more substantial weight loss than older medications like Contrave.
Another theory involves reduced nutrient intake. Semaglutide suppresses appetite, leading to lower consumption of essential nutrients like protein, vital for hair growth. Gastrointestinal side effects like nausea and vomiting can further decrease appetite and nutrient absorption.
Whether the risk of hair loss outweighs the benefits depends on the individual’s reasons for taking the medication (diabetes or obesity) and the severity of their condition. Diabetics might be more willing to accept the risk compared to someone using semaglutide for cosmetic weight loss, according to Sodhi.
Studies on the long-term effects of GLP-1 drugs are crucial in helping people weigh the risks and benefits. Sodhi emphasizes the importance of understanding potential side effects before starting these medications.
“`